Originally scheduled to be a 60-month project in total, beginning October 2016 and ending September 2021, the Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) project has been extended by 12 months to now come to an end in September 2022. The Innovative Medicines Initiative (IMI) has officially approved the request for an extension to the project in order to ensure the full delivery of the project objectives, within the original financial resources. This extension will allow to complete delivery of the work plan, by specifically finalising tasks and activities which are essential to address key project objectives. Due to the global COVID-related events, some of these have suffered considerable delays, which would not be recoverable within the initial duration of the project.
COVID-19 brought the recruitment to a complete halt in mid-March 2020 and also impacted the data analysis. Within the Diagnostic and Patient Management Study, the extension of twelve months will allow the team to achieve both data quality and full delivery of key objectives, such as health economic outcome analyses, crucial elements of the AMYPAD project. With recruitment starting to resume and additional Parent Cohorts being added to the AMYPAD Prognostic and Natural History Study, the extension of twelve months will allow the study to deliver on study objectives, and it will also facilitate the data integration across all cohorts to its further data analysis in the study.
The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA. This article reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
